Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study.

Trial Profile

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Diabetic neuropathies; Fibromyalgia
  • Focus Therapeutic Use
  • Acronyms ExPAND
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jun 2012 Actual patient number (42) added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top